Laura Knoll concentrates her practice in the areas of mergers and acquisitions and general corporate matters, advising public and private companies in a broad range of transactional and corporate contexts, including acquisitions and divestitures, leveraged buyouts, securities law compliance, shareholder activism defense and corporate governance.


Ms. Knoll was named a 2020 Rising Star in Life Sciences by Law360, and has been recognized in Chambers USA and The Legal 500 U.S. She also received the Emerging Leaders Award from The M&A Advisor in 2016.

Some of her significant representations include:

  • Ionis Pharmaceuticals in its acquisition of the remaining outstanding stake of Akcea Therapeutics for $500 million; 
  • CerSci Therapeutics in its sale to ACADIA Pharmaceuticals for up to $939.5 million;
  • ArQule in its sale to Merck for $2.7 billion;
  • WeWork in an $8 billion transaction in which SoftBank provided financing to the company and proposed acquiring a majority of its outstanding shares through a tender offer;
  • Alder in its sale to Lundbeck for up to $1.95 billion;
  • Array BioPharma in its $11.4 billion acquisition by Pfizer;
  • Highbridge Capital Management in its acquisition of assets from Pernix Therapeutics, structured as a Chapter 11 credit bid;
  • WeWork in its $6 billion investment from SoftBank; 
  • United Natural Foods in its acquisition of SUPERVALU for $2.9 billion, including assumption of outstanding debt and liabilities;
  • Hasbro in its $522 million acquisition of Saban Brands’ Power Rangers and other entertainment assets;    
  • Kelso & Company and affiliates of Blue Wolf Capital Partners in connection with the acquisition of Jordan Health Services from Palladium Equity Partners, and Kelso in connection with the concurrent merger of Jordan Health Services with Great Lakes Caring and National Home Health Care under a combined entity jointly owned with affiliates of Blue Wolf;
  • WeWork in its $4.4 billion investment from SoftBank Group and SoftBank Vision Fund
  • Ultragenyx Pharmaceutical in its successful topping bid for Dimension Therapeutics;
  • Tobira Therapeutics, Inc. in its sale to Allergan for up to $1.7 billion;
  • Qlik Technologies Inc. in its $3 billion acquisition by Thoma Bravo, LLC;
  • EMC Corporation in its $67 billion acquisition by Denali Holding Inc., the parent company of Dell Inc.;
  • Banco BTG Pactual S.A. in its $1.7 billion acquisition of BSI SA from Assicurazioni Generali S.p.A. and sale of BSI SA to EFG International AG;
  • Valeant Pharmaceuticals International, Inc. in its $1 billion acquisition of Sprout Pharmaceuticals, Inc., plus a share of future profits based on achievement of milestones;
  • Dendreon Corporation in its Chapter 11 filing and proposed restructuring of $620 million of convertible notes and in its sale of assets to Valeant Pharmaceuticals International, Inc. for $495 million;
  • XL Group plc in its $4.1 billion acquisition of Catlin Group Limited;
  • Arthur T. Demoulas in his and the other Class B shareholders’ acquisition of Demoulas Super Markets, Inc. (Market Basket) of the Class A common stock of Demoulas Super Markets, Inc.;
  • Savient Pharmaceuticals, Inc. in its Chapter 11 filing and sale of assets to Crealta Pharmaceuticals LLC for $120 million;
  • OfficeMax Incorporated in its $1.2 billion merger of equals with Office Depot, Inc.;
  • funds managed by Kelso & Company and StoneRiver Group, L.P. in connection with the merger of Progressive Medical, Inc. and PMSI, Inc.;
  • Westport Innovations Inc. in the restructuring of its 50/50 joint venture with Cummins Inc.;
  • FBL Financial Group, Inc. in its $440 million sale of EquiTrust Life Insurance Company to affiliates of Guggenheim Partners, LLC;
  • BJ Services Company in its $5.5 billion acquisition by Baker Hughes Incorporated;
  • Esselte Corporation in its acquisition of American Pad & Paper LLC from affiliates of Arcapita Bank B.S.C.(c);
  • Retail Ventures, Inc. in its divestitures of Filene’s Basement and Value City Department Stores;
  • UGL Limited in its $400 million acquisition of UNICCO Service Company;
  • Group Dental Service, Inc. in its sale of a controlling interest to Coventry Health Care, Inc.;
  • Regeneron Pharmaceuticals, Inc. in its $312 million sale of an approximately 15 percent equity stake to Sanofi-Aventis SA;
  • The Travelers Companies, Inc. in its sale of Mendota Insurance Company to Kingsway America, Inc.; and
  • Textron Inc. in the $630 million sale of its Textron Fastening Systems unit to affiliates of Platinum Equity LLC.



  • J.D., Harvard Law School, 2005
  • B.A., Harvard University, Harvard College, 2002


  • Massachusetts
  • New York

Laura P. Knoll

Partner, Mergers and Acquisitions